Register for our free email digests:
Latest From ES Cell International Pte. Ltd.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2014.
BioTime has entered into an exclusive licence agreement with Cornell University for the worldwide development and commercialisation of technology developed at Weill Cornell Medical College for the differentiation of human embryonic stem cells into vascular endothelial cells.
South Korea has had an unsteady early relationship with stem cell research and the country has yet to recover fully from the high-profile Hwang Woo-Suk cloning scandal of 2006. This South Korean scientist famously and fraudulently reported to have succeeded in creating human embryonic stem (hES) cells by nuclear transfer. The scandal received widespread coverage in the media and dealt a terrible blow to the country on the embryonic stem cell research stage. Yet, the hero status bestowed on Dr Hwang before his downfall indicated that Asian governments supported, and that their communities were ready for, stem cell therapies.
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Infectious & Viral Diseases
- Commonwealth Serum Laboratories
- Parent & Subsidiaries
- CSL Ltd.
- Senior Management
- Paul Perreault, CEO & Mng. Dir.
- Contact Info
Phone: (61) 3 9389 1911
45 Poplar Rd.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.